OncoMatch/Clinical Trials/NCT06257394

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

Is NCT06257394 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Dasatinib(Sprycel) arm and Non-Dasatinib(Sprycel) arm for acute lymphoblastic leukemia, pediatric.

Phase 2RecruitingHyoung Jin KangNCT06257394Data as of May 2026

Treatment: Dasatinib(Sprycel) arm · Non-Dasatinib(Sprycel) arm — Very high-risk acute lymphoblastic leukemia

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Lymphoblastic Leukemia

Biomarker criteria

Required: BCR fusion with ABL1 (Philadelphia chromosome-positive t(9;22)(q34;q11))

Philadelphia chromosome-positive t(9;22)(q34;q11)

Required: TCF3 fusion with HLF (E2A-HLF translocation-positive)

E2A-HLF(Hepatic Leukemia Factor) translocation-positive

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify